The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.

IF 2.9 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

中国疾病预防控制中心周报 Pub Date : 2025-09-26 DOI:10.46234/ccdcw2025.212

Qingjun Chen, Wenwu Yin, Zhenggang Zhu, Chuanlin Wang

{"title":"The Clinical Advantages of Anti-Rabies Monoclonal Antibodies in Post-Exposure Prophylaxis - Worldwide, 2016-2025.","authors":"Qingjun Chen, Wenwu Yin, Zhenggang Zhu, Chuanlin Wang","doi":"10.46234/ccdcw2025.212","DOIUrl":null,"url":null,"abstract":"<p><p>Post-exposure prophylaxis (PEP) represents the critical intervention for preventing rabies and comprises three essential components: thorough wound cleansing, vaccination, and administration of rabies immunoglobulin (RIG) or monoclonal antibodies (mAbs) for category III exposures. The World Health Organization (WHO) endorses the use of mAb cocktails as an effective replacement for RIG in PEP protocols. Since 2016, four anti-rabies monoclonal antibodies (RmAbs) have received clinical approval for use in India and China. This article provides an overview of the current research status of RmAb. By reviewing clinical studies related to RmAb, it highlights the clinical advantages of RmAb over HRIG in terms of efficacy, accessibility, safety, acceptability, and clinical application in special populations. Additionally, it explores the future clinical prospects of RmAb, including their use in extremely high-risk cases, their impact on circulating antibodies, and their potential role in rabies treatment.</p>","PeriodicalId":69039,"journal":{"name":"中国疾病预防控制中心周报","volume":"7 39","pages":"1258-1262"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518957/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国疾病预防控制中心周报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46234/ccdcw2025.212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Post-exposure prophylaxis (PEP) represents the critical intervention for preventing rabies and comprises three essential components: thorough wound cleansing, vaccination, and administration of rabies immunoglobulin (RIG) or monoclonal antibodies (mAbs) for category III exposures. The World Health Organization (WHO) endorses the use of mAb cocktails as an effective replacement for RIG in PEP protocols. Since 2016, four anti-rabies monoclonal antibodies (RmAbs) have received clinical approval for use in India and China. This article provides an overview of the current research status of RmAb. By reviewing clinical studies related to RmAb, it highlights the clinical advantages of RmAb over HRIG in terms of efficacy, accessibility, safety, acceptability, and clinical application in special populations. Additionally, it explores the future clinical prospects of RmAb, including their use in extremely high-risk cases, their impact on circulating antibodies, and their potential role in rabies treatment.

查看原文本刊更多论文

抗狂犬病单克隆抗体在暴露后预防中的临床优势-全球，2016-2025。

暴露后预防（PEP）是预防狂犬病的关键干预措施，包括三个基本组成部分：彻底清洗伤口，接种疫苗，以及III类暴露时使用狂犬病免疫球蛋白（RIG）或单克隆抗体（mab）。世界卫生组织（世卫组织）赞同使用单抗鸡尾酒作为PEP方案中RIG的有效替代品。自2016年以来，已有四种抗狂犬病单克隆抗体（rmab）在印度和中国获得临床批准使用。本文综述了RmAb的研究现状。通过回顾与RmAb相关的临床研究，强调RmAb在疗效、可及性、安全性、可接受性和特殊人群的临床应用方面优于HRIG的临床优势。此外，它还探讨了RmAb未来的临床前景，包括它们在高危病例中的应用，它们对循环抗体的影响，以及它们在狂犬病治疗中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国疾病预防控制中心周报

CiteScore

5.90

自引率

0.00%

发文量